1075715-57-9

Usage

Uses

Used in Pharmaceutical Synthesis:
(S)-1-(3-CHLOROPHENYL)PROPAN-1-AMINE is used as a building block in the synthesis of various pharmaceuticals and drug compounds. Its unique reactivity and chiral properties make it a key component in the creation of new medications with potential therapeutic applications.
Used in Drug Development:
In the field of drug development, (S)-1-(3-CHLOROPHENYL)PROPAN-1-AMINE serves as a crucial intermediate for the design and synthesis of novel drugs. Its ability to interact with biological targets in a stereoselective manner is essential for the development of drugs with improved efficacy and reduced side effects.
Used in Neurological and Psychiatric Treatments:
(S)-1-(3-CHLOROPHENYL)PROPAN-1-AMINE has potential applications in the treatment of neurological and psychiatric disorders such as depression and anxiety. Its chiral nature allows for the development of enantiomer-specific therapies that can target specific receptors or pathways involved in these conditions, potentially leading to more effective treatments with fewer side effects.
Used in Organic Synthesis:
In the broader field of organic synthesis, (S)-1-(3-CHLOROPHENYL)PROPAN-1-AMINE is utilized as a versatile reagent for the preparation of a wide range of organic compounds. Its reactivity and the presence of a chiral center make it a valuable tool for the synthesis of enantiomerically pure compounds, which are important in various chemical and pharmaceutical applications.

Upstream product

• 925-90-6 ethylmagnesium bromide 
• 587-04-2 m-Chlorobenzaldehyde 
• 766-84-7 3-chloro-benzonitrile 
• 34841-35-5 3'-chloro-propiophenone 

Relevant academic research and scientific papers

Kinetic Resolution of Benzylamines via Palladium(II)-Catalyzed C-H Cross-Coupling

A Pd(II)-catalyzed enantioselective C-H cross-coupling of benzylamines via kinetic resolution has been achieved using chiral mono-N-protected α-amino-O-methylhydroxamic acid (MPAHA) ligands. Both chiral benzylamines and ortho-arylated benzylamines are obtained in high enantiomeric purity. The use of a readily removable nosyl (Ns) protected amino group as the directing group is a crucial practical advantage. Moreover, the ortho-arylated benzylamine products could be further transformed into chiral 6-substituted 5,6-dihydrophenanthridines as important structural motifs in natural products and bioactive molecules.

THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS

Disclosed are novel compounds of Formula (IA) and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and ischemia reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound of Formula (IA).

ISOTHIAZOLE DIOXIDES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS

Disclosed are novel compounds of the formula (IA): and the pharmaceutically acceptable salts and solvates thereof. D and E are different groups wherein one is N and the other is CR50. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound of formula IA.

2-Mercaptoimidazoles, a new class of potent CCR2 antagonists

We describe the synthesis and SAR of a new class of CCR2 antagonists based on a 2-mercaptoimidazole scaffold. The initial lead 1a was optimized to the 3,4-disubstituted analogues 1p-(S) and 1q-(S), which have IC50 values in the MCP-1 induced Ca

3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands

There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.

THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS

Disclosed are novel compounds of the formula (IA) and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, acute pain, acute and chronic inflammatory pain, and neuropathic pain using a compound of formula (IA).

3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands

There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.